HBY Hybridon

Hybridon Announces the Appointment of Robert W. Karr, M.D. to its Board of Directors CAMBRIDGE, Mass., June 17 /PRNewswire-FirstCall/ -- Hybridon, Inc. (AMEX:HBY) today announced the election of Robert W. Karr, M.D. to the Company's Board of Directors. Dr. Karr was elected as a class II director for a term expiring at the Company's annual meeting in 2006. Hybridon's Board of Directors now includes eight members and Dr. Karr's appointment increases the number of independent directors to six. Dr. Karr served as Sr. Vice President of Strategic Management at Pfizer Global Research and Development until 2004, where he played a central role in designing Pfizer's R & D strategy. Prior to joining Pfizer, Dr. Karr served as Vice President, Research & Development Strategy at Warner-Lambert and at G. D. Searle. "We are delighted to welcome Dr. Karr," said James B. Wyngaarden, M.D., Chairman of Hybridon's Board of Directors. "His appointment adds extensive pharmaceutical management and drug development expertise to the Hybridon board. Bob will be an important resource in helping to chart Hybridon's strategic priorities as we move our Toll-like Receptor therapeutics programs forward into a number of disease areas." "I am pleased to be associated with Hybridon, a company whose technology platforms have the potential to treat unmet clinical needs in infectious diseases, cancer and asthma/allergies," said Dr. Karr. "I look forward to lending my support to Hybridon as the Company continues to advance its development programs based on TLR therapeutics." Dr. Robert W. Karr received his M.D. from the University of Texas Medical Branch in Galveston in 1975 and his residency and fellowship training at Washington University School of Medicine, St. Louis, Missouri. He was a member of the faculty of the University of Iowa College of Medicine from 1982 to 1991, and later served as Associate Clinical Professor of Medicine at the Washington University School of Medicine from 1991 to 1999. Dr. Karr is board-certified in Internal Medicine and Rheumatology and is licensed in the state of Missouri. He is a member of the American College of Rheumatology and the American Association of Immunologists. Dr. Karr is also a member of the Board of Directors of GTx, Inc. About Hybridon Hybridon, Inc. is developing novel therapeutics based on synthetic nucleic acid chemistry for the treatment of cancer, asthma/allergies, and infectious diseases. Hybridon's proprietary Immune Modulatory Oligonucleotide (IMO(TM)) drug candidates are designed to modulate immune responses through Toll-like receptors, the body's first line of defense against disease. The Company's nucleic acid chemistry expertise has also generated a portfolio of partnered products and intellectual property, creating the potential for long-term value for Hybridon. For more information please visit our website at http://www.hybridon.com/. This press release contains forward-looking statements concerning Hybridon that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Hybridon's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Hybridon's technology will advance through the clinical trial process and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if such products receive approval, they will be successfully distributed and marketed; whether Hybridon's cash resources will be sufficient to fund product development; and such other important factors as are set forth under the caption "Risk Factors" in Hybridon's Quarterly Report on Form 10-Q filed on May 10, 2005, which important factors are incorporated herein by reference. Hybridon disclaims any intention or obligation to update any forward-looking statements. Contacts: Hybridon, Inc. MacDougall Biomedical Communications 617-679-5500, x5517 508-647-0209 x12 Robert G. Andersen Douglas MacDougall E-mail: Email: DATASOURCE: Hybridon, Inc. CONTACT: Robert G. Andersen of Hybridon, Inc., +1-617-679-5500, ext 5517, ; or Douglas MacDougall of MacDougall Biomedical Communications, +1-508-647-0209, ext 12, Web site: http://www.hybridon.com/

Copyright